Literature DB >> 19447870

Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases.

Beatriz M Carreno1, Joel R Garbow, Grant R Kolar, Erin N Jackson, John A Engelbach, Michelle Becker-Hapak, Leonidas N Carayannopoulos, David Piwnica-Worms, Gerald P Linette.   

Abstract

PURPOSE: Immunodeficient mice serve as critical hosts for transplantation of xenogeneic cells for in vivo analysis of various biological processes. Because investigators typically select one or two immunodeficient mouse strains as recipients, no comprehensive study has been published documenting differences in human tumor engraftment. Taking advantage of the increased metastatic potential of RhoC-expressing human (A375) melanoma cells, we evaluate four immunodeficient mouse strains: severe combined immunodeficiency (scid), nonobese diabetic (NOD)-scid, NOD-scid beta2m(null), and NOD-scid IL2Rgamma(null) as xenograft tumor recipients. EXPERIMENTAL
DESIGN: Bioluminescence, magnetic resonance imaging, and histopathology were used to monitor serial tumor growth. Natural killer (NK) cell function was examined in each mouse strain using standard (51)Chromium release assays.
RESULTS: Melanoma metastases growth is delayed and variable in scid and NOD-scid mice. In contrast, NOD-scid beta2m(null) and NOD-scid IL2Rgamma(null) mice show rapid tumor engraftment, although tumor growth is variable in NOD-scid beta2m(null) mice. NK cells were detected in all strains except NOD-scid IL2Rgamma(null), and in vitro activated scid, NOD-scid, and NOD-scid beta2m(null) NK cells kill human melanoma lines and primary melanoma cells. Expression of human NKG2D ligands MHC class I chain-related A and B molecules renders melanoma susceptible to murine NK cell-mediated cytotoxicity and killing is inhibited by antibody blockade of murine NKG2D.
CONCLUSIONS: Murine NKG2D recognition of MICA/B is an important receptor-ligand interaction used by NK cells in immunodeficient strains to limit engraftment of human tumors. The absolute NK deficiency in NOD-scid IL2Rgamma(null) animals makes this strain an excellent recipient of melanoma and potentially other human malignancies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19447870      PMCID: PMC2697956          DOI: 10.1158/1078-0432.CCR-08-2502

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  49 in total

1.  Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D.

Authors:  Leonidas N Carayannopoulos; Olga V Naidenko; Daved H Fremont; Wayne M Yokoyama
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

2.  Impairment of NK cell function by NKG2D modulation in NOD mice.

Authors:  Kouetsu Ogasawara; Jessica A Hamerman; Honor Hsin; Shunsuke Chikuma; Helene Bour-Jordan; Taian Chen; Thomas Pertel; Claude Carnaud; Jeffrey A Bluestone; Lewis L Lanier
Journal:  Immunity       Date:  2003-01       Impact factor: 31.745

3.  Costimulation of multiple NK cell activation receptors by NKG2D.

Authors:  Emily L Ho; Leonidas N Carayannopoulos; Jennifer Poursine-Laurent; Jeremy Kinder; Beatrice Plougastel; Hamish R C Smith; Wayne M Yokoyama
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

4.  Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.

Authors:  Daniela Pende; Paola Rivera; Stefania Marcenaro; Chien-Chung Chang; Roberto Biassoni; Romana Conte; Marek Kubin; David Cosman; Soldano Ferrone; Lorenzo Moretta; Alessandro Moretta
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

5.  Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.

Authors:  A Diefenbach; A M Jamieson; S D Liu; N Shastri; D H Raulet
Journal:  Nat Immunol       Date:  2000-08       Impact factor: 25.606

6.  beta2 microglobulin-deficient (B2m(null)) NOD/SCID mice are excellent recipients for studying human stem cell function.

Authors:  O Kollet; A Peled; T Byk; H Ben-Hur; D Greiner; L Shultz; T Lapidot
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

7.  Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin.

Authors:  D Pende; C Cantoni; P Rivera; M Vitale; R Castriconi; S Marcenaro; M Nanni; R Biassoni; C Bottino; A Moretta; L Moretta
Journal:  Eur J Immunol       Date:  2001-04       Impact factor: 5.532

8.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

9.  PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.

Authors:  LauraL Carter; Lynette A Fouser; Jason Jussif; Lori Fitz; Bija Deng; Clive R Wood; Mary Collins; Tasuku Honjo; Gordon J Freeman; Beatriz M Carreno
Journal:  Eur J Immunol       Date:  2002-03       Impact factor: 5.532

10.  Regulation of human short-term repopulating cell (STRC) engraftment in NOD/SCID mice by host CD122+ cells.

Authors:  Leonard D Shultz; Scott J Banuelos; Jean Leif; Michael C Appel; Melody Cunningham; Karen Ballen; Lisa Burzenski; Dale L Greiner
Journal:  Exp Hematol       Date:  2003-06       Impact factor: 3.084

View more
  28 in total

1.  Quantitative analysis of tumor burden in mouse lung via MRI.

Authors:  Vanessa K Tidwell; Joel R Garbow; Alexander S Krupnick; John A Engelbach; Arye Nehorai
Journal:  Magn Reson Med       Date:  2011-09-27       Impact factor: 4.668

2.  Imaging primary lung cancers in mice to study radiation biology: in regard to Kirsch et al. (Int J Radiat Oncol Biol Phys 2010;76:973-977).

Authors:  Joel R Garbow; Joseph J H Ackerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-03-01       Impact factor: 7.038

Review 3.  The importance of animal models in tumor immunity and immunotherapy.

Authors:  Sadna Budhu; Jedd Wolchok; Taha Merghoub
Journal:  Curr Opin Genet Dev       Date:  2013-12-29       Impact factor: 5.578

4.  Initial testing of lenalidomide by the pediatric preclinical testing program.

Authors:  C Patrick Reynolds; Min H Kang; Stephen T Keir; Richard Gorlick; E Anders Kolb; Richard Lock; John M Maris; Hernan Carol; Christopher L Morton; Catherine A Billups; Malcolm A Smith; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2011-02-25       Impact factor: 3.167

Review 5.  Challenges in pre-clinical testing of anti-cancer drugs in cell culture and in animal models.

Authors:  Harm HogenEsch; Alexander Yu Nikitin
Journal:  J Control Release       Date:  2012-03-14       Impact factor: 9.776

6.  A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.

Authors:  Aaron Y Chang; Tao Dao; Ron S Gejman; Casey A Jarvis; Andrew Scott; Leonid Dubrovsky; Melissa D Mathias; Tatyana Korontsvit; Victoriya Zakhaleva; Michael Curcio; Ronald C Hendrickson; Cheng Liu; David A Scheinberg
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

Review 7.  Two-photon microscopy in pulmonary research.

Authors:  Ruben G Nava; Wenjun Li; Andrew E Gelman; Alexander S Krupnick; Mark J Miller; Daniel Kreisel
Journal:  Semin Immunopathol       Date:  2010-06-30       Impact factor: 9.623

8.  Humanized mouse models to study human diseases.

Authors:  Michael A Brehm; Leonard D Shultz; Dale L Greiner
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-04       Impact factor: 3.243

9.  Sex-dependent liver colonization of human melanoma in SCID mice--role of host defense mechanisms.

Authors:  Judit Dobos; Anita Mohos; József Tóvári; Erzsébet Rásó; Tamás Lőrincz; Gergely Zádori; József Tímár; Andrea Ladányi
Journal:  Clin Exp Metastasis       Date:  2012-12-01       Impact factor: 5.150

10.  Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.

Authors:  Theresa Falls; Dominic Guy Roy; John Cameron Bell; Marie-Claude Bourgeois-Daigneault
Journal:  ILAR J       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.